Skip to content

Side by side

Fat Blaster vs Retatrutide

Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.

Fat Blaster and Retatrutide compared on what BioAlmanac records.
 Fat BlasterRetatrutide
What it isA marketing name, not a formula. What is in the syringe varies by clinic, and no version of it has been shown to cause weight loss.An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere.
EvidenceHow much human evidence exists, not how well it works.PreclinicalEarly human trials
Regulatory statusReviewed 2026-08-18Not an approved medicine. Sold as a compounded preparation, which means it is mixed by a pharmacy for a specific patient rather than manufactured and reviewed as a product. The FDA does not review compounded preparations for safety or effectiveness before they are sold.Investigational. Not approved for human use in any jurisdiction. Sold only as a research chemical, with no manufacturing standard behind that label.
RoutesIntramuscularSubcutaneous
Half-lifeNot recorded144 hours
Cheapest per mgVials only, read from vendors' own listings and dated on the price index.Not recorded$1.25/mg
Median per mgNot recorded$5.17/mg
Vendors with a priceNot recorded37
Storage once mixedNothing to reconstitute. Compounded preparations carry a beyond-use date rather than a manufacturer's expiry, and it is usually short.Refrigerated at 2–8 °C. Do not freeze.

Compare two other compounds · The full price index

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.